The partnership between the Danish pharmaceutical giant and the splashy telehealth firm Hims & Hers was strained from the ...

Telehealth company Hims & Hers is facing a growing number of U.S. investor lawsuits after Novo Nordisk's decision last month ...

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

Novo Nordisk A/S (NYSE: NVO) is one of the high-margin pharma stocks to buy now. Berenberg has reaffirmed its Hold rating on ...

The Danish government and the foundation behind Novo Nordisk A/S will invest €80 million ($93 million) in a Microsoft-powered ...

Novo Nordisk Foundation & Denmark invest €80M in a Microsoft-powered quantum computer to boost Nordic tech innovation.

The company will offer a generic version of semaglutide in the country after Novo Nordisk let its patent expire there. Hims & ...

In Novo Nordisk A/S’s home country of Denmark, the popularity of weight-loss drugs is fueling economic growth, but local ...

Investing.com -- Denmark’s export and investment fund EIFO and the Novo Nordisk (NYSE: NVO) Foundation are investing €80 ...

Clever Culture’s APAS is now on trial with Novo Nordisk, and if it delivers, this one machine could unlock a global pharma ...

Novo Nordisk reportedly failed to pay its annual fees to maintain the patent rights in Canada, opening the door to cheaper ...

Novo Nordisk (NVO) closed the most recent trading day at $65.29, moving 2.61% from the previous trading session.